关于广州市品高软件股份有限公司 首次公开发行股票并在科创板上市之保荐总结报告书 民生证券股份有限公司 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为广州市品 高软件股份有限公司（以下简称"品高股份"、"公司"或"发行人"）首次公开发行 股票并在科创板上市项目的保荐机构，负责品高股份上市后的持续督导工作，持 续督导期间为2021年12月30日至2024年12月31日。2024年12月31日，持续督导期 已届满，民生证券根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板股票上市规则》等有关规定，出具本保荐总结报告书。 一、保荐机构及保荐代表人承诺 性陈述或重大遗漏，本保荐机构及保荐代表人对其真实性、准确性、完整性承担 法律责任。 的任何质询和调查。 理办法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 民生证券股份有限公司 | | 注册地址 | 中国（上海）自由贸易试验区浦明路8号 | | 办公地址 | 中国（上海）自由贸易试验区浦明路8号 | | 法定代表人 | 顾伟 | | 保荐代表人 | 袁莉敏、刘思超 ...

| 运动·快乐·梦想 | 证券代码：002780 | 公告编号：2025-029 | 证券简称：三夫户外 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 北京三夫户外用品股份有限公司 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 | | | | | | | | | | | | 误导性陈述或重大遗漏。 | 根据中国证券监督管理委员会发布的《监管规则适用指引——发行类第 | 7 号》及相 | | | | | | | | | | | 关规定，北京三夫户外用品股份有限公司（以下简称"公司"或"本公司"）现将截至 | 一、 | 前次募集资金情况 | | | | | | | | | | | 经中国证券监督管理委员会证监许可2021173 号文《关于核准北京三夫户外用品 | 股份有限公司非公开发行股票的批复》的核准，公司向特定投资者非公开发行人民币普 | | | | | | | | | | | | 12,218,843 股，每股发行价人民币为 | 15. ...

Core Viewpoint - The report provides an overview of the fundraising activities and the utilization of the raised funds by Beijing Sanfu Outdoor Products Co., Ltd, confirming that the funds have been used in accordance with regulatory guidelines and for the intended projects [1][2]. Fundraising Situation - The company raised a total of RMB 193.18 million through a non-public offering of 12,218,843 shares at RMB 15.81 per share, with net proceeds amounting to RMB 185.99 million after deducting issuance costs of RMB 7.19 million [2][5]. - The funds were deposited into a dedicated account on September 27, 2021, and verified by RSM China [1][2]. Fund Management - The company established a fundraising management system to ensure the proper use of funds, adhering to principles of regulation, safety, efficiency, and transparency [2]. - A tripartite supervision agreement was signed with Beijing Bank and Xinda Securities to manage the funds [2]. Fund Utilization - As of December 31, 2024, the total amount of funds utilized was RMB 185.99 million, with RMB 146.70 million allocated to the committed investment project and RMB 39.30 million used to supplement working capital [2][3]. - The company generated interest income of RMB 2.27 million and investment income of RMB 2.31 million from the funds [3][5]. Project Adjustments - The company adjusted the internal structure of the investment project, reallocating funds from facility and equipment purchases to store upgrades and marketing for the X-BIONIC brand [3][4]. - The adjustments were made to enhance operational efficiency and focus on brand promotion amidst industry challenges [4]. Remaining Funds - As of December 31, 2024, there were no remaining funds from the previous fundraising activities, as all funds were utilized or reallocated [4][5]. - The company permanently supplemented working capital with the remaining funds, totaling RMB 39.30 million, after the closure of the fundraising account [5]. Project Performance - The X-BIONIC project has shown stable revenue growth, with the company focusing on expanding sales channels and enhancing marketing efforts [4][5]. - The project has met its expected performance metrics, with a cumulative production utilization rate indicating successful implementation [5].

南京泉峰汽车精密技术股份有限公司 截至 2024 年 12 月 31 日止 前次募集资金使用情况报告的鉴证报告 KPMG Huazhen LLP 毕马威华振会计师事务所 Oriental Plaza 中国北京 Beijing 100738 东方广场毕马威大楼 8 层 China 邮政编码:100738 Telephone +86 (10) 8508 5000 电话 +86 (10) 8508 5000 Fax +86 (10) 8518 5111 传真 +86 (10) 8518 5111 Internet kpmg.com/cn 网址 kpmg.com/cn 关于南京泉峰汽车精密技术股份有限公司 前次募集资金使用情况报告的鉴证报告 毕马威华振专字第 2503408 号 南京泉峰汽车精密技术股份有限公司董事会： 我们接受委托，对后附的南京泉峰汽车精密技术股份有限公司（以下简称"泉峰汽车公 司"）于 2019 年 5 月通过首次公开发行股票、2021 年 9 月通过公开发行可转换公司债券、 证业务，就前次募集资金使用情况报告是否在所有重大方面按照中国证券监督管理委员会颁 布的《监管规则适用指引——发行类第 7 ...

国泰海通证券股份有限公司关于杭州爱科科技股份有限公司2024年度持续督导跟踪报告显示，2024年， 爱科科技营业收入同比增长17.58%，主要受益于境内外下游行业需求稳定增长及公司市场开拓。归属 于上市公司股东的净利润同比下降11.00%，主要因加大研发投入、并购费用及人力成本上升。公司持 续强化核心技术优势，截至2024年末，已获授权发明专利72项、实用新型专利89项及软件著作权147 项。2024年研发投入同比增长28.48%，累计申请境内外专利265项。募集资金使用合规，累计已使用 223,381,158.67元，剩余17,529,159.12元。控股股东、实际控制人等持有的公司股份不存在质押、冻结及 减持情形。公司不存在重大违规事项。 截至2025年5月9日收盘，爱科科技（688092）报收于21.17元，较上周的20.65元上涨2.52%。本周，爱 科科技5月8日盘中最高价报21.66元。5月6日盘中最低价报20.65元。爱科科技当前最新总市值17.51亿 元，在专用设备板块市值排名170/177，在两市A股市值排名4978/5145。 国泰海通证券股份有限公司关于杭州爱科科技股份有限公司首次公开发 ...

东亚药业发行费用合计1.02亿元，其中，保荐机构东兴证券股份有限公司获得保荐及承销费用6143.87万 元。 据公司4月30日披露的《东兴证券股份有限公司关于浙江东亚药业股份有限公司2024年度募集资金存放 与使用情况专项核查报告》，根据中国证监会批复(证监许可〔2023〕1165号)，公司获准向不特定对象 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减变动幅度(%) | | 营业收入 | 190, 921, 213. 83 | 352. 582. 674. 10 | -45. 85 | | 归属于上市公司股东的净 | -6, 919, 576. 54 | 24, 039, 198. 04 | -128.78 | | 利润 | | | | | 归属于上市公司股东的扣 | -10, 505, 893. 27 | 20, 376, 579. 89 | -151. 56 | | 除非经常性损益的净利润 | | | | | 经营活动产生的现金流量 | -134, 527, 926. 86 | -97, 089, 771. 88 ...

Group 1 - The company announced a change in accounting policies based on new regulations issued by the Ministry of Finance, which will take effect on January 1, 2024, and December 31, 2024, respectively [2][3][4] - The change in accounting policies is deemed reasonable and will not have a significant impact on the company's financial status, operating results, or cash flow [5][6] Group 2 - The company appointed Zhongqin Wanxin Certified Public Accountants as the financial and internal control audit institution for the year 2025, with an audit fee of 2.9 million yuan [6][13] - Zhongqin Wanxin has been providing audit services to the company for 22 consecutive years and possesses the necessary qualifications for auditing listed companies [8][9] Group 3 - The company expects a total of 69.62 million yuan in daily related transactions for the year 2025 with its affiliated companies [21] - The related transactions are considered routine and do not pose significant risks to the company's operations or financial health [28][35] Group 4 - The company plans to conclude the "Lianhua Qingwen series product capacity enhancement project" and terminate the "Lianhua Qingwen capsule international registration project," reallocating the surplus funds to supplement working capital permanently [41][42] - The total surplus funds from these projects amount to 21.46 million yuan, which will be used to support the company's daily operations [52][53] Group 5 - The company will hold its 2024 annual general meeting on May 26, 2025, allowing shareholders to participate both in person and via online voting [56][58] - The meeting will address various resolutions that have been approved by the board and supervisory committee [65][66]

Core Viewpoint - The company proposes a cash dividend distribution plan for the fiscal year 2024, with a total distribution amounting to 111,748,483.20 RMB, which represents 42.11% of the net profit attributable to shareholders [3][86]. Company Overview - The company, Hunan Haili Chemical Co., Ltd., operates in the pesticide and chemical industry, which is currently facing challenges such as policy adjustments and changing market demands, leading to a steady decline in total pesticide production in China [6][7]. - Despite these challenges, the overall scale of the pesticide industry remains significant, with increasing market concentration as leading companies accelerate consolidation [6][7]. Financial Performance - For the fiscal year 2024, the company achieved a net profit of 26,540,200 RMB, with total assets amounting to 458,633,360 RMB and equity attributable to shareholders of 315,956,150 RMB as of December 31, 2024 [10][11]. - The company’s total unallocated profits at the end of the fiscal year were 1,225,036,629.08 RMB, and the capital reserve was 1,195,551,098.18 RMB [3][86]. Dividend Distribution Plan - The proposed dividend distribution is set at 2 RMB per 10 shares (including tax), based on a total share capital of 558,742,416 shares as of December 31, 2024 [3][86]. - The plan does not include any capital reserve conversion to increase share capital, and the specific date for the dividend distribution will be announced later [4][87]. Board and Supervisory Committee Decisions - The board of directors and the supervisory committee have approved the annual report, financial settlement report, and the profit distribution plan, which will be submitted for approval at the annual shareholders' meeting [12][63][64]. - The board meeting was held on April 25, 2025, with all members present, ensuring compliance with legal and regulatory requirements [12][56]. Industry Context - The pesticide industry in China is characterized by a fragmented competitive landscape, with major players focusing on research and development to enhance their market positions [6][7]. - The company is also involved in the production of lithium battery materials, which is experiencing growth due to rising demand for electric vehicles [7][9].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001287 证券简称：中电港 公告编号：2025-010 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求（2022年修订）》《深圳 证券交易所上市公司自律监管指引第1号——主板上市公司规范运作（2023年12月修订）》等相关规 定，深圳中电港技术股份有限公司（以下简称"公司"）2024年度募集资金存放与使用的具体情况说明如 下： 一、募集资金的基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会2023年3月16日发布的《关于同意深圳中电港技术股份有限公司首次公开 发行股票注册的批复》（证监许可〔2023〕584号），公司首次向社会公开发行人民币普通股 18,997.5024万股，发行价格11.88元/股，募集资金总额225,690.33万元，扣除相关发行费用后实际募集资 金净额213,331.22万元。募集资金已于2023年4月3日划至公司指定账户，经信永中和会计师事务所（特 殊普通合伙）审验并出具《关于深 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 若在分配方案实施前公司总股本由于可转债转股、股份回购、股权激励行权等原因发生变动的，公司则 以未来实施分配方案时股权登记日的总股本为基数，按照现金分红总额不变的原则对分配比例进行相应 调整。 三、现金分红方案的具体情况 （一）现金分红方案不触及其他风险警示情形 ■ （二）现金分红方案合理性说明 公司本次利润分配方案符合《公司法》《企业会计准则》《上市公司监管指引第3号一一上市公司现金 分红》以及《公司章程》等规定，符合公司确定的利润分配政策、利润分配计划等相关承诺，该利润分 配方案合法、合规。 四、相关风险提示 1、本次利润分配方案披露前，公司严格按照法律、法规、规范性文件及公司制度的有关规定，严格控 制内幕信息知情人范围，对相关内幕信息知情人履行了保密和严禁内幕交易的告知义务，同时对内幕信 息知情人及时备案，防止内幕信息的泄露。 2、本利润分配方案需经公司2024年年度股东大会审议通过后实施，尚存在不确定性，敬请广大投资者 注意投资风险。 五、备查文件 1、公司第二届董事会第六次会议决议； 2、公司第二届监事会第六次会议决议； 特此公告。 江西威尔高电子股份 ...